@article{8922a1e6b9bd4a8486a1633e1ca94120,
title = "Adjunctive Clavulanic Acid Abolishes the Cefazolin Inoculum Effect in an Experimental Rat Model of Methicillin-Sensitive Staphylococcus aureus Endocarditis",
abstract = "We tested the ability of clavulanic acid to restore the efficacy of cefazolin against Staphylococcus aureus TX0117, which exhibits the cefazolin inoculum effect (CzIE). In the rat infective endocarditis model, the coadministration of cefazolin plus clavulanic acid resulted in a significant reduction of bacterial counts (7.1 0.5 log10 CFU/g) compared to that with cefazolin alone (2 0.6 log10 CFU/g; P 0.0001). The addition of a -lactamase inhibitor may be a viable strategy for overcoming the CzIE.",
keywords = "Animal models, Cefazolin, Clavulanic acid, Infective endocarditis, Inoculum effect, Staphylococcus aureus",
author = "Miller, {William R.} and Singh, {Kavindra V.} and Arias, {Cesar A.} and Murray, {Barbara E.}",
note = "Funding Information: This work was supported in part by NIH-NIAID grants R21/R33 AI121519 and K24 AI121296, a UTHealth Presidential award, and a University of Texas System STARS award to C.A.A. and UTHealth Center for Antimicrobial Resistance and Microbial Genomics (CARMiG) seed funds to W.R.M. Funding Information: The funding agency had no role in experimental design, data collection, or interpretation of this work. W.R.M. has received grants and/or honoraria from Achaogen and Merck. K.V.S. has received grants from Paratek Pharmaceuticals and Merck. C.A.A. has received grants from Merck and MeMed. B.E.M. has received grants from Paratek Pharmaceuticals and Merck and served on the advisory board for Cempra and Paratek. Funding Information: This work was supported in part by NIH-NIAID grants R21/R33 AI121519 and K24 AI121296, a UTHealth Presidential award, and a University of Texas System STARS award to C.A.A. and UTHealth Center for Antimicrobial Resistance and Microbial Genomics (CARMiG) seed funds to W.R.M. The funding agency had no role in experimental design, data collection, or interpretation of this work. W.R.M. has received grants and/or honoraria from Achaogen and Merck. K.V.S. has received grants from Paratek Pharmaceuticals and Merck. C.A.A. has received grants from Merck and MeMed. B.E.M. has received grants from Paratek Pharmaceuticals and Merck and served on the advisory board for Cempra and Paratek. Publisher Copyright: Copyright {\textcopyright} 2018 American Society for Microbiology. All Rights Reserved.",
year = "2018",
month = nov,
doi = "10.1128/AAC.01158-18",
language = "English (US)",
volume = "62",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "11",
}